Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

Clinical trial NCT05352893 · COMPLETED

Trial details

NCT number: NCT05352893
Sponsor: Vanda Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Generalized Pustular Psoriasis

Start date: 2022-04-14
Primary completion: 2023-08-17
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.